Balyasny Asset Management
HRMY icon

Balyasny Asset Management’s Harmony Biosciences HRMY Stock Holding History

Balyasny Asset Management’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.81M Buy
+64,600
New +$2.12M ﹤0.01% 1830

Other funds holding HRMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Balyasny Asset Management's HRMY Position: Q4 2023 in Review

Balyasny Asset Management sold out of Harmony Biosciences (HRMY) in Q4 2023, closing a stake of 254,650 shares — an estimated $8.34M sold.

Balyasny Asset Management first reported a position in HRMY in Q3 2021 and held it in 4 quarters. The position peaked at $15.3M in Q1 2023. 221 funds tracked by Wall St. Rank hold HRMY as of Q4 2023.

  • Balyasny Asset Management reported no remaining Harmony Biosciences position as of Q4 2023 after selling out during the quarter.
  • Balyasny Asset Management sold 254,650 Harmony Biosciences shares in Q4 2023, an estimated $8.34M.
  • Balyasny Asset Management first reported a position in Harmony Biosciences in Q3 2021 and held it in 4 quarters.
  • Balyasny Asset Management's Harmony Biosciences position peaked at $15.3M in Q1 2023.
  • 221 funds tracked by Wall St. Rank held Harmony Biosciences as of Q4 2023.

Based on Balyasny Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.